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httpense.Abstract Objective: To detect the pulmonary involvement in asymptomatic secondary APS
patients by pulmonary function tests (PFTs) and chest multislice HRCT angiography. Comparing
the pulmonary ﬁndings to those of asymptomatic SLE patients without APS was considered.
Patients and methods: Thirty-four SLE patients with APS and another 34 SLE patients without
APS and with a negative ACL test were included as control. All patients were asymptomatic for any
pulmonary manifestations. Plain chest X-ray, HRCT angiography and PFTs were performed for all
patients in an attempt to assess the pulmonary vasculature and lung parenchyma. Disease activity
was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) while
assessment of organ damage was made using the Systemic Lupus International Collaborating Clin-
ics/ACR (SLICC/ACR) index.
Results: There were abnormal pulmonary CT ﬁndings in 11 (32.35%) of the asymptomatic sec-
ondary APS patients with an obvious association to lupus anticoagulants. However, plain X-ray
showed basal atelectasis and/or elevation of the copulae in four patients. Pulmonary abnormalities
included a high frequency of pulmonary artery aneurysms (20.59%) thrombosis, basal atelectasis,
embolism, bronchiectasis, pleural effusion and thickening. The SLEDAI and SLICC were signiﬁ-
cantly higher in APS patients. More SLE patients without APS were receiving hydroxychloroquine
which suggests a protective role on the thromboembolic events occurring in APS.274.
(T. Gheita).
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218 T. Gheita et al.Conclusion: Multislice HRCT pulmonary angiography, with its multiplanar capability, vascular
reconstruction and high quality, is useful in demonstrating the entire thoracic spectrum in asymp-
tomatic APS patients. Particular concern about the medications used in APS could prevent the risk
of developing noticeable thromboembolic events.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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Systemic lupus erythematosus (SLE) is an autoimmune disease
characterized by disturbances in immune mechanisms and
involvement of multiple systems and organs. Tissue damage
and dysfunction are mediated by autoantibodies and immune
complex formation with the lungs among the organ systems
commonly involved. The pulmonary manifestations usually oc-
cur in patients with multisystem disease and include pleural
involvement, parenchymal disease, pulmonary vascular disease
anddiaphragmatic dysfunction.Manifestationsmay range from
sub-clinical abnormalities to life threatening disorders.Many of
the pulmonary manifestations characteristic of SLE are seen in
the antiphospholipid syndrome (APS) as well, in both the pri-
mary and secondary syndrome [1]. Although respiratory
involvement in SLE is frequent, yet the diagnosismaybedifﬁcult
because of the heterogeneity of the anatomical and clinical pre-
sentations. A precise diagnosis is crucial as new immunosup-
pressive drugs have considerably improved the prognosis [2].
The APS is a disorder associated with hypercoagulability,
thrombocytopenia, and thromboembolic phenomena [3]. Sin-
gle vessel (large/medium) involvement or multiple vascular
occlusions may cause a wide variety of presentations. Any
combination of vascular occlusive events may occur in the
same individual, and the time interval between them also varies
considerably from weeks to months or even years. Rapid chro-
nological occlusive events occurring over days to weeks is
termed ‘‘catastrophic’’ APS. Most of these complications
may be ascribed to the hypercoagulable state of which anti-
phospholipid (aPL) antibodies appear either to be ‘‘markers’’
or intimately connected with the highly complex coagulation
mechanisms resulting in thrombotic occlusions [4].
Pulmonary manifestations of APS include pulmonary
thromboembolism, pulmonary hypertension, and respiratory
failure associated with diffuse pulmonary inﬁltrates [3,5,6]. It
is an autoimmune condition whereby pathogenic aPL antibod-
ies cause vascular thrombosis and/or recurrent miscarriage,
and carries a high burden of morbidity and mortality [7]. A
broad spectrum of pulmonary disease may occur in APS, the
most common being pulmonary thromboembolism and pul-
monary hypertension [8]. This spectrum of pulmonary disor-
ders in patients with aPL antibodies is sometimes referred to
as the ‘‘antiphospholipid lung syndrome’’, and further includes
adult respiratory distress syndrome (ARDS) and intra-alveolar
hemorrhages. Timely diagnosis and correct therapy, as well as
good patient-doctor collaboration, can result in stabilization
of the patient’s condition [9]. Otherwise, the ‘‘catastrophic’’
variant of the APS which is an accelerated form of this sys-
temic autoimmune condition may results in multiorgan failure
because of multiple small vessel occlusions [10].
In the course of SLE, APS is responsible for diverse respi-
ratory manifestations. Pulmonary embolism is common andthe site of the causal venous thrombosis is frequently unusual.
Pulmonary hypertension may be a consequence of repeated
embolism or may belong to the primary idiopathic variety.
Pulmonary manifestations may also result from left-sided
heart failure due to mitral or aortic valve abnormalities, myo-
cardial infarction or a speciﬁc myocardiopathy. APS is proba-
bly involved in the occurrence of some cases of ARDS. Long
term secondary prevention of recurrent thrombosis is a central
point in the management of APS [11]. Pulmonary involvement
in APS include a wide range of clinical presentations, ranging
from mild dyspnea to respiratory insufﬁciency requiring
mechanical ventilation and can occur alone or simultaneously
with other manifestations of APS which may range from mild
to severe [5].
The presence of aPL antibodies including anticardiolipin
antibodies (ACL) and lupus anticoagulant (LA) associated
with venous and/or arterial thrombotic phenomena and fetal
losses deﬁne the APS [11–13]. The strongest predictor of fea-
tures related to APS is the LA. Therapy of thrombosis is based
on long-term oral anticoagulation and patients with arterial
events should be treated aggressively. Primary thrombopro-
phylaxis is recommended in patients with SLE and APS with
hydroxychloroquine considered as a potential additional treat-
ment for this syndrome. Possible future therapies for non-preg-
nant APS patients are statins, rituximab, and new
anticoagulant drugs [14]. The most prevalent pathology in
APS was thrombosis; venous (42.6%) and arterial (22%).
Thrombocytopenia occurs in 12.1% and pulmonary thrombo-
embolism was present in 20.6% [15].
Patients with APS may present with diffuse alveolar hemor-
rhage resulting in mild to life threatening symptoms. Prompt
and thorough evaluation to conﬁrm the diagnosis and treat-
ment with corticosteroids usually leads to rapid improvement.
However, Bronchoscopy and bronchoalveolar lavage with or
without biopsy often aid in conﬁrming the diagnosis [16].
The aim of the present study was to detect the pulmonary
involvement in asymptomatic secondary APS patients by PFTs
and multislice HRCT. Comparing the pulmonary ﬁndings to
those of asymptomatic SLE patients without APS was
considered.
Patients and methods
Thirty-four SLE patients with APS and asymptomatic for any
pulmonary manifestations were included. Another 34 SLE pa-
tients without APS and with a negative ACL test were included
as control. All patients were fulﬁlling the updated ACR revised
criteria for the classiﬁcation of SLE [17] and recruited from the
Rheumatology and Internal medicine out-patient Clinics of
Cairo University Hospitals. The diagnosis of deﬁnite second-
ary APS was according to International consensus statement
on classiﬁcation criteria [18].
Table 1 The demographic and clinical manifestations in the
SLE and APS patients.
Features mean ± SD SLE (34) APS (34) Sig. p
Age (years) 29 ± 6.19 31.05 ± 7.64 0.23
Disease duration (years) 5.06 ± 3.39 5.05 ± 2.78 0.99
BMI 25.6 ± 3.478 27.39 ± 3.33 0.054
SLEDAI 4.18 ± 4.41 7.85a ± 6.36 0.007
SLICC 0.94 ± 1.3 2.47a ± 2.03 0.001
Steroid dose (mg/day) 15.08 ± 9.97 18.97 ± 11.94 0.16
Clinical manifestations No. (%)
Arthritis 28 (82.35) 23 (67.65)
Serositis 12 (35.29) 12 (35.29)
Nephritis 14 (41.18) 22 (64.71)
Neuropsychiatric 13 (38.24) 13 (38.24)
Hematological 15 (44.12) 22 (64.71)
Mucocutaneous 23 (67.65) 15 (44.12)
Cardiovascular 4 (11.76) 5 (14.71)
Hypertension 2 (5.88) 7 (20.59)
Pulmonary hypertension 1 (2.94) 8 (23.53)
Vasculitis 0 (0) 2 (5.88)
Alopecia 12 (35.29) 14 (41.18)
Fibromyalgia syndrome 5 (14.71) 4 (11.76)
a Signiﬁcantly different at p< 0.05.
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evant laboratory investigations were performed for all the pa-
tients. Plain chest X-ray and pulmonary High resolution CT
angiography was performed for all patients in an attempt to
assess the pulmonary vasculature and lung parenchyma. Dis-
ease activity was assessed using the Systemic Lupus Erythema-
tosus Disease Activity Index (SLEDAI) [19] while assessment
of organ damage was made using the Systemic Lupus Interna-
tional Collaborating Clinics/ACR (SLICC/ACR) index [20].
Plain X-ray, echocardiography and pulmonary function
tests (PFT) including the FVC, FEV1 and the FEV1/FVC
(%) were performed to all patients. Standard high-resolution
CT technique was carried out with precontrast scans through
a lesion suspected of being an aneurysm. A post contrast study
of 1-mm collimation multislice CT acquisition covering a
range from the aortic arch to the base of the heart in 8–10 s,
was performed. The images are reconstructed in the standard
soft-tissue window for the mediastinal structures and in the
high resolution window settings for the parenchymal changes,
as well as the peripheral pulmonary vessels.
The study has been approved by local ethics committee and
it conforms to the standards currently applied in Cairo Univer-
sity Teaching Hospitals.
Statistics: Analysis of data was performed with a statistical
package for the social sciences (SPSS) version 15. Data were
presented as mean ± standard deviation and percentage.
Mann–Whitney test was used for analysis of two non paramet-
ric quantitative data. Correlation was performed by Pearson
correlation coefﬁcient. P value was considered signiﬁcant if
<0.05.Results
Sixty-eight female SLE patients; 34 with secondary APS and
another 34 without APS and with negative ACL antibodies
were included. They were all asymptomatic for any pulmonary
manifestation and had no history of any chest disease. Forty-
nine were married, 12 divorced and 7 single; there was a his-
tory of abortion in 46 and DVT occurred in 37. None of the
patients were smoking. The demographic features and clinical
manifestations as well as the results of the investigations of the
studied patients are shown in Tables 1 and 2. Table 3 shows
the pulmonary ﬁndings in SLE patients with and without APS.
Besides the steroids, hydroxychloroquine was received by
17 APS patients and in 29 with SLE only, azathioprine in 21
APS and 28 SLE, while cyclophosphamide was received by 9
APS and 14 SLE patients. All patients with APS were receiving
oral anticoagulants while the SLE patients were not. Renal
biopsy grade for those with lupus nephritis was 1.91 ± 1.68
in SLE patients with APS. The mean systolic blood pressure
was 123.1 ± 16.61 mm Hg and the diastolic 80.15 ±
10.19 mm Hg. In SLE patients without APS had a renal biopsy
grade of 1.5 ± 1.8; the mean systolic blood pressure was
118.71 ± 16.88 mm Hg and the diastolic 77.42 ± 11.89 mm
Hg.
The ACL antibodies were low positive (10–20 U/L) in 22
(64.71%) and moderately high (>208 U/L) in 12 (35.29%)
of the APS patients who also had a positive Lupus anticoagu-
lant test. The ANA was positive in all APS patients and in
91.18% of SLE without APS, while the anti-dsDNA was posi-
tive in 76.47% and 70.59%, respectively. Thrombocytopeniawas present in 9 (26.47%) APS and 4 (11.76%) SLE only
patients.
The PFT results are shown in Table 3. Abnormal pulmon-
ary CT angiographic ﬁndings were found in 11 (32.35%) of the
asymptomatic APS patients and in only 3 (8.82%) of the SLE
patients without APS. Nine (81.81%) of the patients with
radiological ﬁndings had a positive lupus anticoagulant test.
The plain X-ray was normal in all patients except in 4 APS pa-
tients showing basal atelectasis and/or elevation of the copu-
lae. Elevation of the copula was bilateral in three of the APS
patients. All the other pulmonary ﬁndings were revealed by
the multislice HRCT as presented in Table 3. Pulmonary vas-
cular abnormalities included pulmonary artery aneurysms
were of varying sizes in 7 APS patients (20.59%) being located
mostly in the lower lobe segments more on the right side with 2
(5.88%) of them associated with the main right and left pul-
monary artery ectasia.
The SLEDAI signiﬁcantly negatively correlated with the
PFTs; FVC (r 0.3, p 0.01), FEV1 (0.44, p 0.000), FEV1/
FVC (r -0.29, p 0.02). There was no obvious correlation of
the SLEDAI with the ACL antibodies level. Pulmonary ﬁnd-
ings are shown in Figs. 1–3.
Discussion
In the present study, the patients were asymptomatic for any
pulmonary manifestation and not known to have any chest
disease. The pulmonary function tests including FVC, FEV1
and FEV1/FVC were reduced in APS patients compared to
SLE only patients. The percent of predicted FEV1 was signif-
icantly reduced compared to the corresponding value in SLE
patients. Similarly, FVC and FEV1 were reduced in SLE pa-
tients with APS or aPL antibodies compared to SLE only cases
and were signiﬁcantly reduced compared to primary APS pa-
tients. Impaired pulmonary function tests were frequently de-
tected in asymptomatic SLE patients with or without APS [21].
Table 2 Laboratory investigations of the APS and SLE patients.
Laboratory ﬁndings mean ± SD SLE (34) APS (34) Sig. p
ESR (mm/1st hour) 47.19 ± 26.9 49.24 ± 26.8 0.76
Hb (g/dl) 10.63 ± 2.2 10.95 ± 2.51 0.58
WBC (thousands/mm3) 6.77 ± 3.43 8.17 ± 6.53 0.28
Platelets (thousand/mm3) 293.9 ± 122.5 268.8 ± 96.7 0.36
Urea (mg/dl) 30 ± 10.3 36.3 ± 21.48 0.16
Urine protein (g/24 h) 0.63 ± 0.71 0.99 ± 1.15 0.16
Albumin (g/dl) 3.67 ± 0.65 3.86 ± 0.67 0.29
AST (U/L) 31.79 ± 19.42 38.53 ± 33.49 0.33
ALT (U/L) 23.37 ± 12.46 31.3 ± 31.89 0.19
Alk phosphatase (IU/L) 79.91 ± 35.95 99.53 ± 45.06 0.06
Anti-Ro (U/ml) 12.41 ± 11.26 21.34 ± 34.09 0.15
Anti-La (U/ml) 9.8 ± 5.57 15.58 ± 27.4 0.24
ACL (IgG) 5.79 ± 2.11 20.34a ± 11.6 0.000
ACL (IgM) 7.62 ± 1.81 15.62a ± 14.58 0.003
C3 (mg/dl) 0.72 ± 0.47 0.76 ± 0.52 0.81
C4 (mg/dl) 0.20 ± 0.15 0.16 ± 0.13 0.33
a Signiﬁcantly different at p< 0.05.
Table 3 The pulmonary function test and chest radiological ﬁndings (X-ray and multislice HRCT) in SLE and APS patients.
Pulmonary ﬁndings mean ± SD SLE (34) APS (34) Sig. p
Pulmonary Function Tests
FVC (Litres) 3.81 ± 0.76 3.67 ± 0.94 0.51
(% Predicted) 90.92 ± 5.99 89.63 ± 7.63 0.44
FEV1 (litres) 3.11 ± 0.75 2.84 ± 0.9 0.18
(% Predicted) 88.1 ± 6.89 81.89a ± 13.21 0.02
FEV1/FVC (%) 97.32 ± 9.95 91.63 ± 14.83 0.07
Chest X-ray and CT ﬁndings
Basal atelectasis 2 (5.88) 5 (14.71)
Bronchiectasis 0 (0) 3 (8.82)
Elevated copula 2 (5.88) 6 (17.65)
Pulmonary artery aneurysm 0 (0) 7 (20.59)
Pulmonary embolisms 0 (0) 3 (8.82)
Pulmonary artery thrombosis 0 (0) 5 (14.71)
Pleural eﬀusion 2 (5.88) 3 (8.82)
Pleural thickening 1 (2.94) 2 (5.88)
a Signiﬁcantly different at p< 0.05.
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(32.35%) of the asymptomatic secondary APS patients com-
pared to 3 (8.82%) SLE patients. The APS patients mostly
had a positive LA result. The plain X-ray was normal in all pa-
tients except in 4 with APS showing basal atelectasis and/or
elevation of the copulae. Multislice HRCT is useful in demon-
strating the entire spectrum of thoracic manifestations of APS,
is noninvasive and provides excellent delineation of the vessel
lumen and wall, perivascular tissues, the lung parenchyma,
pleura and mediastinal structures [22]. Several pulmonary
abnormalities were found in the patients including a high fre-
quency of pulmonary artery aneurysms (20.59%) followed by
pulmonary artery thrombosis, basal atelectasis, pulmonary
embolism, bronchiectasis, pleural effusion and thickening.
In the present study silent pulmonary embolism was present
in 3 APS patients. Symptomatic pulmonary manifestations in
APS are relatively rare compared to other clinical signs of this
disease [9]. Silent pulmonary emboli are part of the disease
spectrum of antiphospholipid syndrome [23]. Pulmonaryembolism and deep-vein thrombosis are the two components
of a single disease called venous thromboembolism. Approxi-
mately 30% of apparently isolated episodes of pulmonary
embolism are associated with silent deep-vein thrombosis,
and in patients presenting with symptoms of DVT, the fre-
quency of silent pulmonary embolism ranges from 40% to
50% [24].
Pulmonary artery thrombosis was present in 14.71% of the
studied APS patients. Pulmonary microthrombosis is among
the most frequent arterial complications of APS. Timely diag-
nosis of pulmonary manifestations is required due to their
severity and high mortality rate [9]. Vascular thrombosis is
seen in 80.3% of APS patients and involves the pulmonary sys-
tem in 20.4% [25]. Contrarily, it was reported that thrombotic
obstruction at the level of the main and/or proximal pulmon-
ary arteries is rare in APS [6]. Pulmonary involvement occurs
in 68% of catastrophic APS patients and 40% of these patients
died mostly due to an underlying thrombotic microangiopathy
[10]. This conﬁrms the necessity that APS patients are
Figure 1 Bilateral basal atelectatic bands with tenting of the
right copula of the diaphragm.
Figure 2 HRCT chest showing bilateral elevated copulae of the
diaphragm, lobar ﬁbrosis and bronchiactasis.
Figure 3 Transaxial multislice pulmonary CT angiography
showing bilateral saccular pulmonary artery aneurysms, larger
on the right with a nonenhancing hypodense luminal thrombus
extending to the right main pulmonary artery.
Pulmonary involvement in asymptomatic systemic lupus 221thoroughly examined and investigated for any pulmonary
involvement even if asymptomatic so that any serious events
could be early managed.
In this study, pulmonary hypertension was obviously pres-
ent in a quarter of the APS patients compared to SLE (2.94%).
The prevalence of pulmonary hypertension in SLE was 4.2%
and was found to be of mild severity. There was a signiﬁcant
association of lupus anticoagulants and presence of pulmonary
hypertension in cases of APS which suggests that thrombosis
may play an important role in pulmonary hypertension with
SLE which is treatable [26]. Pulmonary hypertension was evi-
dently present only in SLE patients with aPL antibodies or
with APS [21].The present ﬁndings show that the pulmonary involvement
in APS patients was frequently associated with LA. The asso-
ciation between clinical features of APS and antiphospholipid
antibody is signiﬁcant. LA is a stronger risk factor for throm-
bosis and abnormal pregnancy than ACL and the prevalence
of a positive ACL and LA was 77% and 62.3%, respectively
[25]. In the current study, there was no correlation between
the ACL antibodies and the severity of clinical manifestations
in APS. However, high levels of ACL were appreciated with a
high percentage of venous and arterial thrombosis. The pres-
ence of ACL constitutes a prothrombotic risk factor [15].
In the present study, hydroxychloroquine was received by
only half the APS patients while it was received by 85.29%
of SLE only patients. Furthermore, more patients with SLE
only were receiving azathioprine and cyclophosphamide. How-
ever, all patients with APS were receiving oral anticoagulants
while the SLE patients were not. A protective effect of hydrox-
ychloroquine on thrombosis in SLE patients especially those
with antiphospholipids may be considered a new approach
of thrombosis prevention in APS [26].
A special care of the medication strategy for APS patients
should be well thought-out. An optimum combination ther-
apy, including hydroxychloroquine, in SLE patients without
APS seems to have a protective role on the thromboembolic
pulmonary manifestations. This may throw light on the pro-
tective effect that may be shown by hydroxychloroquine and
the important cautious use of anticoagulation for DVT in
asymptomatic APS patients. Currently the only proven treat-
ment in APS is long-term anticoagulation, which is not effec-
tive in all patients and carries risk of haemorrhage [7]. The
management of antiphospholipid antibody-positive patients
has been focused on utilizing anti-thrombotic medications
such as heparin or warfarin. It is highly likely that the current
‘anti-thrombotic’ approach will be replaced by an ‘immuno-
modulatory’ one in the near future to include hydroxychloro-
quine and statins in APS [13].
In conclusion, multislice CT pulmonary angiography, with
its multiplanar capability, vascular reconstruction and high
quality, is useful in demonstrating the entire spectrum of
thoracic manifestations in asymptomatic APS patients, most
222 T. Gheita et al.notably pulmonary artery aneurysms. Particular concern
about the medications used in APS could prevent the risk of
developing noticeable thromboembolic events. Follow up of
these asymptomatic APS cases and including a larger number
are recommended for a broader overview on this extremely
important issue.
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